Vimarsana
Biggest News Aggregation in the World

Page 27 - Jeff Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Mclaughlin Today - Breaking & Trending Today

GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa - Vimarsana News

GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa

ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis. 1 Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying response to treatments. We are excited to launch Project Afr...

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 - Vimarsana News

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection Trial targeted to begin in 1Q:2021 at multiple sites across the UK SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc....

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - Vimarsana News

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

News Category Global Banking & Finance Reviews Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 – Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17, 2020 — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today an...

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US - Vimarsana News

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US Approval builds on nearly 10 years of experience in lupus News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most c...

ViiV Healthcare Announces Positive CHMP Opinion for Rukobia (fostemsavir), a First-in-Class Attachment Inhibitor for the Treatment of Adults With Multidrug-Resistant HIV With Few Treatment Options Available - Vimarsana News

ViiV Healthcare Announces Positive CHMP Opinion for Rukobia (fostemsavir), a First-in-Class Attachment Inhibitor for the Treatment of Adults With Multidrug-Resistant HIV With Few Treatment Options Available

(1) Findings from pivotal phase III BRIGHTE study demonstrated that the majority (60%) of heavily treatment-experienced adults randomised to receive fostemsavir with an optimised background therapy achieved and maintained viral suppression at 96 weeks Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Prod...